Takeda Pharmaceutical Co. Ltd.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more
Takeda Pharmaceutical Co. Ltd. (TKPHF) - Net Assets
Latest net assets as of December 2025: $7.65 Trillion USD
Based on the latest financial reports, Takeda Pharmaceutical Co. Ltd. (TKPHF) has net assets worth $7.65 Trillion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.42 Trillion) and total liabilities ($7.77 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.65 Trillion |
| % of Total Assets | 49.61% |
| Annual Growth Rate | 7.4% |
| 5-Year Change | 33.97% |
| 10-Year Change | 244.87% |
| Growth Volatility | 31.75 |
Takeda Pharmaceutical Co. Ltd. - Net Assets Trend (2001–2025)
This chart illustrates how Takeda Pharmaceutical Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Takeda Pharmaceutical Co. Ltd. (2001–2025)
The table below shows the annual net assets of Takeda Pharmaceutical Co. Ltd. from 2001 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $6.94 Trillion | -4.65% |
| 2024-03-31 | $7.27 Trillion | +14.47% |
| 2023-03-31 | $6.35 Trillion | +11.81% |
| 2022-03-31 | $5.68 Trillion | +9.78% |
| 2021-03-31 | $5.18 Trillion | +9.51% |
| 2020-03-31 | $4.73 Trillion | -8.45% |
| 2019-03-31 | $5.16 Trillion | +155.95% |
| 2018-03-31 | $2.02 Trillion | +3.51% |
| 2017-03-31 | $1.95 Trillion | -3.09% |
| 2016-03-31 | $2.01 Trillion | -8.84% |
| 2015-03-31 | $2.21 Trillion | -13.16% |
| 2014-03-31 | $2.54 Trillion | +14.27% |
| 2013-03-31 | $2.22 Trillion | +7.31% |
| 2012-03-31 | $2.07 Trillion | -3.03% |
| 2011-03-31 | $2.14 Trillion | -1.30% |
| 2010-03-31 | $2.16 Trillion | +5.40% |
| 2009-03-31 | $2.05 Trillion | -11.57% |
| 2008-03-31 | $2.32 Trillion | -5.63% |
| 2007-03-31 | $2.46 Trillion | +4.80% |
| 2006-03-31 | $2.35 Trillion | +17.34% |
| 2005-03-31 | $2.00 Trillion | +12.38% |
| 2004-03-31 | $1.78 Trillion | +13.60% |
| 2003-03-31 | $1.57 Trillion | +7.43% |
| 2002-03-31 | $1.46 Trillion | +16.74% |
| 2001-03-31 | $1.25 Trillion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Takeda Pharmaceutical Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 20.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.19 Trillion | 17.12% |
| Common Stock | $1.69 Trillion | 24.44% |
| Other Comprehensive Income | $2.35 Trillion | 33.91% |
| Other Components | $1.70 Trillion | 24.53% |
| Total Equity | $6.94 Trillion | 100.00% |
Takeda Pharmaceutical Co. Ltd. Competitors by Market Cap
The table below lists competitors of Takeda Pharmaceutical Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dell Technologies Inc
NYSE:DELL
|
$47.62 Billion |
|
Nippon Telegraph & Telephone Corp
PINK:NPPXF
|
$47.81 Billion |
|
AIRBNB INC. DL-01
F:6Z1
|
$47.87 Billion |
|
Swiss Re AG
PINK:SSREF
|
$47.98 Billion |
|
Danone SA
PA:BN
|
$47.46 Billion |
|
United Rentals Inc
NYSE:URI
|
$47.22 Billion |
|
Comfort Systems USA Inc
NYSE:FIX
|
$47.20 Billion |
|
BASF SE NA O.N.
OTCQX:BFFAF
|
$47.09 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Takeda Pharmaceutical Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,273,264,000,000 to 6,935,084,000,000, a change of -338,180,000,000 (-4.6%).
- Net income of 107,928,000,000 contributed positively to equity growth.
- Dividend payments of 302,498,000,000 reduced retained earnings.
- Share repurchases of 51,860,000,000 reduced equity.
- Other comprehensive income decreased equity by 157,395,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $107.93 Billion | +1.56% |
| Dividends Paid | $302.50 Billion | -4.36% |
| Share Repurchases | $51.86 Billion | -0.75% |
| Other Comprehensive Income | $-157.40 Billion | -2.27% |
| Other Changes | $65.64 Billion | +0.95% |
| Total Change | $- | -4.65% |
Book Value vs Market Value Analysis
This analysis compares Takeda Pharmaceutical Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-03-31 | $1374.20 | $30.07 | x |
| 2002-03-31 | $1609.08 | $30.07 | x |
| 2003-03-31 | $1774.65 | $30.07 | x |
| 2004-03-31 | $2009.49 | $30.07 | x |
| 2005-03-31 | $2258.03 | $30.07 | x |
| 2006-03-31 | $2649.97 | $30.07 | x |
| 2007-03-31 | $2782.02 | $30.07 | x |
| 2008-03-31 | $2688.34 | $30.07 | x |
| 2009-03-31 | $2487.01 | $30.07 | x |
| 2010-03-31 | $2687.01 | $30.07 | x |
| 2011-03-31 | $2649.72 | $30.07 | x |
| 2012-03-31 | $2548.78 | $30.07 | x |
| 2013-03-31 | $2735.41 | $30.07 | x |
| 2014-03-31 | $3126.12 | $30.07 | x |
| 2015-03-31 | $2717.51 | $30.07 | x |
| 2016-03-31 | $2472.39 | $30.07 | x |
| 2017-03-31 | $2410.34 | $30.07 | x |
| 2018-03-31 | $2538.97 | $30.07 | x |
| 2019-03-31 | $5336.23 | $30.07 | x |
| 2020-03-31 | $3015.88 | $30.07 | x |
| 2021-03-31 | $3287.52 | $30.07 | x |
| 2022-03-31 | $3603.30 | $30.07 | x |
| 2023-03-31 | $4047.54 | $30.07 | x |
| 2024-03-31 | $4602.33 | $30.07 | x |
| 2025-03-31 | $4320.06 | $30.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Takeda Pharmaceutical Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.36%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 2.05x
- Recent ROE (1.56%) is below the historical average (8.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 12.11% | 15.24% | 0.55x | 1.44x | $25.57 Billion |
| 2002 | 16.59% | 23.45% | 0.51x | 1.38x | $93.65 Billion |
| 2003 | 17.33% | 25.98% | 0.51x | 1.31x | $114.99 Billion |
| 2004 | 16.02% | 26.26% | 0.47x | 1.31x | $107.16 Billion |
| 2005 | 13.86% | 24.71% | 0.44x | 1.27x | $77.30 Billion |
| 2006 | 13.34% | 25.84% | 0.40x | 1.30x | $78.41 Billion |
| 2007 | 13.87% | 25.73% | 0.42x | 1.27x | $93.78 Billion |
| 2008 | 15.58% | 25.85% | 0.48x | 1.25x | $127.38 Billion |
| 2009 | 11.65% | 15.24% | 0.56x | 1.37x | $33.24 Billion |
| 2010 | 14.04% | 20.31% | 0.52x | 1.33x | $85.61 Billion |
| 2011 | 11.85% | 17.46% | 0.51x | 1.33x | $38.68 Billion |
| 2012 | 6.17% | 8.23% | 0.42x | 1.78x | $-77.07 Billion |
| 2013 | 6.08% | 8.43% | 0.39x | 1.83x | $-84.75 Billion |
| 2014 | 4.32% | 6.30% | 0.37x | 1.85x | $-140.42 Billion |
| 2015 | -6.82% | -8.20% | 0.41x | 2.01x | $-359.48 Billion |
| 2016 | 4.11% | 4.44% | 0.47x | 1.96x | $-114.70 Billion |
| 2017 | 6.07% | 6.64% | 0.40x | 2.30x | $-74.49 Billion |
| 2018 | 9.36% | 10.56% | 0.43x | 2.06x | $-12.86 Billion |
| 2019 | 2.12% | 5.20% | 0.15x | 2.69x | $-406.83 Billion |
| 2020 | 0.94% | 1.34% | 0.26x | 2.71x | $-428.11 Billion |
| 2021 | 7.27% | 11.76% | 0.25x | 2.50x | $-141.30 Billion |
| 2022 | 4.05% | 6.45% | 0.27x | 2.32x | $-338.24 Billion |
| 2023 | 4.99% | 7.87% | 0.29x | 2.20x | $-318.40 Billion |
| 2024 | 1.98% | 3.38% | 0.28x | 2.08x | $-583.26 Billion |
| 2025 | 1.56% | 2.36% | 0.32x | 2.05x | $-585.58 Billion |
Industry Comparison
This section compares Takeda Pharmaceutical Co. Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. (TKPHF) | $7.65 Trillion | 12.11% | 1.02x | $47.47 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |